Current concepts on active immunization against respiratory syncytial virus for infants and young children

Pediatric Infectious Disease Journal

Volumn 21, Issue 7, 2002, Pages 685-696

  Kneyber, Martin C J ^a   Kimpen, Jan L L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Immunization; Prevention; Respiratory syncytial virus

Indexed keywords

RESPIRATORY SYNCYTIAL VIRUS VACCINE; INACTIVATED VACCINE; RECOMBINANT VACCINE;

ACTIVE IMMUNIZATION; CHILD; CHILDHOOD DISEASE; HUMAN; INFANT; INFANT DISEASE; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RNA VIRUS INFECTION; TEMPERATURE SENSITIVE MUTANT; ANIMAL; CATTLE; FEMALE; FORECASTING; IMMUNIZATION; MALE; MOUSE; NETHERLANDS; PRESCHOOL CHILD; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STANDARD; VACCINATION; VIRUS INFECTION;

ANIMAL; CATTLE; CHILD, PRESCHOOL; FEMALE; FORECASTING; HUMAN; IMMUNIZATION SCHEDULE; IMMUNIZATION, PASSIVE; INFANT; MALE; MICE; NETHERLANDS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VACCINATION; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; ANIMALS; HUMANS;

EID: 0036020188     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200207000-00017     Document Type: Review

References (150)

1. Epidemiology of respiratory syncytial virus infection in Washington DC: III. Composite analysis of eleven consecutive yearly epidemics
2. Respiratory syncytial virus pneumonia in the hospital setting: Length of stay, charges and mortality
3. Risk of primary infection and reinfection with respiratory syncytial virus
4. RSV what we now know
5. Respiratory syncytial virus infection in adults
6. Treatment and prevention of respiratory syncytial virus infection
7. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children
8. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis
9. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
10. Comments on palivizumab (Synagis)
11. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV): A meeting report of the WHO Programme for Vaccine Development
12. Identification of a tenth mRNA of respiratory syncytial virus and assignment of polypeptides to the 10 viral genes
13. The genome of respiratory syncytial virus is a negative-stranded RNA that codes for at least seven mRNA species
14. Advances in prevention of respiratory syncytial virus infections
15. Two distinct subtypes of human respiratory syncytial virus
16. Identification of variable domains of the attachment (G) protein of subgroup A respiratory syncytial viruses
17. Variation in severity of respiratory syncytial virus infections with subtype
18. Respiratory syncytial virus epidemic: Variable dominance of subgroups A and B strains among children, 1981-1986
19. Occurrence of respiratory syncytial virus subtypes in hospitalised children in Cleveland, Ohio from 1985 to 1988
20. Relationship between clinical severity of RSV infection and subtype
21. Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus
22. Respiratory syncytial virus group specific antibody response in nasopharyngeal secretions from infants and children after primary infection
23. Immunity to and frequency of reinfection with respiratory syncytial virus
24. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level
25. Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: Safety and pharmacokinetics
26. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies
27. Cytotoxic lymphocytes in the lungs of mice infected with respiratory syncytial virus
28. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice
29. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus
30. + T cells
31. Respiratory syncytial virus infection is associated with predominant Th-2 like response
32. Peripheral blood cytokine responses and disease severity in respiratory syncytial virus bronchiolitis
33. Comparison of the T helper cell response induced by respiratory syncytial virus and its fusion protein in BALB/c mice
34. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection
35. Monocyte IL-10 production during respiratory syncytial virus bronchiolitis is associated with recurrent wheezing in a one-year follow-up study
36. Risk factors for respiratory syncytial virus associated lower respiratory illnesses in the first year of life
37. Epidemiology of respiratory syncytial virus infection in Washington DC: II. Infection and disease with respect to age, immunologic status, race and sex
38. Neonatal respiratory syncytial virus infection
39. Pediatric Investigators Collaborative Network on Infections in Canada (PIC-NIC) study of admission and management variation in patients hospitalised with respiratory syncytial viral lower respiratory tract infection
40. Local variability in respiratory syncytial virus disease severity
41. Respiratory syncytial virus infection in tropical and developing countries
42. Respiratory syncytial virus
43. Respiratory syncytial virus: A report of a 5-year study at a Children's Hospial
44. Repeated infections with respiratory syncytial virus
45. Respiratory syncytial virus infections, reinfections and immunity: A prospective, longitudinal study in young children
46. Studies on respiratory syncytial virus infection
47. Preterm twins and triplets: A high risk group for severe respiratory syncytial virus infection
48. Meteorological variables and occurrence of respiratory syncytial virus in Urugay
49. Deprivation and bronchiolitis
50. Breast-feeding and respiratory syncytial virus infection
51. Acute bronchiolitis: Predisposing factors and characterisation of infants at risk
52. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia
53. Respiratory syncytial virus infection in infants with congenital heart disease
54. Respiratory syncytial virus infection in children with compromised immune function
55. Respiratory syncytial virus infection in infants with unequal pulmonary perfusion
56. Respiratory syncytial virus infection in children with congenital heart disease: A review
57. Respiratory syncytial virus infections in paediatric liver transplant recipients
58. Differing manifestations of respiratory syncytial virus-associated severe lower respiratory tract infections in human immunodeficiency virus type 1-infected and uninfected children
59. Does prematurity alter the course of respiratory syncytial virus infection?
60. Respiratory syncytial virus puzzle: Clinical features, pathophysiology, treatment and prevention
61. Bronchiolitis
62. Clinical and physiological manifestations of bronchiolitis and pneumonia
63. Risk factors for respiratory syncytial virus associated apnoea
64. Respiratory syncytial virus infections in children admitted to the intensive care unit
65. Clinical observations on mechanical ventilation for respiratory failure in bronchiolitis
66. Intensive care course and outcome of patients infected with respiratory syncytial virus
67. Risk factors for mechanical ventilation in respiratory syncytial virus infection
68. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalised with respiratory syncytial viral lower respiratory tract infection
69. Nosocomial respiratory syncytial virus infections
70. Respiratory syncytial virus infection in young hospitalised children
71. Nosocomial respiratory syncytial virus infection in a newborn nursery
72. Nosocomial respiratory syncytial virus infections in a pediatric department
73. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
74. Respiratory virus immunization: I. A field trial of two inactivated respiratory virus vaccines: An aqueous trivalent parainfluenza virus vaccine and an alumprecipitated respiratory syncytial virus vaccine
75. An epidemiologic study of altered clinical reactivity to respiratory syncytial virus (RSV) infection in children previously vaccinated with an inactivated RS virus vaccine
76. Respiratory syncytial virus vaccines
77. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine
78. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity
79. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern
80. + T cells
81. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10
82. Respiratory syncytial virus infection in paediatric patients
83. Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines
84. Maternal immunization against viral disease
85. Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine
86. The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice
87. Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection
88. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization
89. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease
90. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in BALB/c mice that are similar to those generated by experimental infection
91. Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H
92. Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines
93. Respiratory syncytial virus-specific cell mediated immune responses after vaccination with a purified fusion subunit vaccine
94. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 1:8-36 months old
95. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old
96. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis
97. Sequential annual administration of purifed fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis
98. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia
99. Respiratory syncytial virus purified fusion protein-2 (PFP-2) vaccine in pregnancy
100. Induction of protective immunity in rodens by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment
101. Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunisation with a recombinant G fusion protein, BBG2Na, in aluminum hydroxide
102. Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na
103. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: Influence of adjuvants and maternal antibodies
104. Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na
105. Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate
106. Protection against respiratory syncytial virus (RSV) elicited in mice by plasmid DNA immunization encoding a secreted RSV G protein-derivedantigen
107. Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge
108. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV
109. Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats
110. Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine
111. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses
112. Pathogenesis of RSV lower respiratory tract infection: Implications for vaccine development
113. Construction and characterisation of recombinant vaccinia virus co-expressing a respiratory syncytial virus protein and a cytokine
114. The immunogenicity of subunit vaccines for respiratory syncytial virus after coformulation with aluminum hydroxide adjuvant and recombinant interleukin-12
115. Neonatal DNA immunization with a plasmid encoding an internal viral protein is effective in the presence of maternal antibodies and protects against subsequent viral challenge
116. Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice
117. Protection against respiratory syncytial virus infection by DNA immunization
118. DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation
119. Immune induction and modulation in mice following immunization with DNA encoding F protein of respiratory syncytial virus
120. Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV
121. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH and M2-2 genes are attenuated in vitro and in vivo
122. Chimeric subgroup A respiratory syncytial virus with the glycoproteins substituted by those of subgroup B and RSV without the M2-2 gene are attenuated in African green monkeys
123. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees
124. Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein
125. Respiratory syncytial virus (RSV) F, G M2(22K) and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N protein is relatively short-lived
126. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee
127. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus
128. Protective immune responses induced by the immunization of mice with a recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus
129. Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides
130. Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type14 vector is immunogenic
131. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus and a tickborne encephalitis virus
132. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines
133. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines
134. Immunogenicity and pathogenicity of temperature-sensitive modified respiratory syncytial virus in adult volunteers
135. Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers
136. Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines
137. Attenuated temperature-sensitive respiratory syncytial virus mutants generated by cold adaptation
138. The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the ts phenotype following replication in vivo
139. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization
140. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy
141. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and human adults, infants, and children
142. Evaluation of live rRSV A2 vaccines in infants and young children
143. Serum neutralizing antibody titers of seropositive chimpanzees immunized with vaccines coformulated with natural fusion and attachment proteins of respiratory syncytial virus
144. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults
145. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates
146. + T cell epitopes on the fusion (F) and attachment (G) proteins of bovine respiratory syncytial virus (BRSV)
147. Chimeric HRSV/BRSV viruses with enhanced expression of antigenic determinants as live-attenuated vaccines
148. Chimeric bovine respiratory syncytial viurs with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): Effects on host range and evaluation as a live-attenuated HRSV vaccine
149. Recombinant bovine/human parainfluenze virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3